Primary cutaneous diffuse large B-cell lymphoma, leg type: Clinicopathologic features and prognostic analysis in 60 cases

Archives of Dermatology

Volumn 143, Issue 9, 2007, Pages 1144-1150

  Grange, Florent ^a   Beylot Barry, Marie ^b   Courville, Phillipe ^c   Maubec, Eve ^d   Bagot, Martine ^f   Vergier, Béatrice ^b   Souteyrand, Pierre ^g   Machet, Laurent ^h   Dalac, Sophie ⁱ   Esteve, Eric ^j   Templier, Isabelle ^k   Delaporte, Emmanuel ^l   Avril, Marie Françoise ^e,m   Robert, Caroline ^m   Dalle, Stephane ⁿ   Laroche, Liliane ^o   Delaunay, Michele ^p   Joly, Pascal ^c   Wechsler, Janine ^f   Petrella, Tony ⁱ  

^a SERVICE DE DERMATOLOGIE   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

^d BICHAT HOSPITAL   (France)

^e Paris Descartes University   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h SERVICE DE DERMATOLOGIE   (France)

ⁱ HÔPITAL DU BOCAGE   (France)

^j Hôpital Porte Madeleine   (France)

^k HÔPITAL MICHALLON   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ HÔTEL DIEU   (France)

^o AVICENNE HOSPITAL   (France)

^p HÔPITAL PELLEGRIN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; INTERFERON REGULATORY FACTOR 4; LACTATE DEHYDROGENASE; PROTEIN; PROTEIN BCL 2; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL FEATURE; FEMALE; FRANCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LEG DISEASE; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SKIN LYMPHOMA; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEG; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS;

EID: 34548842519     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.9.1144     Document Type: Article

References (27)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas [published online ahead of print February 3, 2005]. Blood. 2005;105(10):3768-3785.
2. Burg G, Kempf W, Cozzio A, et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 2005;32(10):647-674.
3. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005;153(5):874-880.
4. Willemze R, Meijer CJLM, Scheffer E, et al. Diffuse large cell lymphomas of follicle center cell origin presenting in the skin: a clinicopathologic and immunologic study of 16 patients. Am J Pathol. 1987;126(2):325-333.
5. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma: clinicopathologic and immunologic study of 83 cases. Cancer. 1991;67(9):2311-2326.
6. Pimpinelli N, Santucci M, Mori M, Vallecchi C, Giannotti B. Primary cutaneous B-cell lymphoma: a clinically homogeneous entity? J Am Acad Dermatol. 1997;37(6):1012-1016.
7. Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology. 1993;23(2):117-125.
8. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol. 2005;141(9):1139-1145.
9. Grange F, Hedelin G, Joly P, et al; The French Study Group on Cutaneous Lymphomas. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. Blood. 1999;93(11):3637-3642.
10. Fink-Puches R, Zenahlik P, Bäck B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99(3):800-805.
11. Kodama K, Massone C, Chott A, Smolle J, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106(7):2491-2497.
12. Zinzani PL, Quaglino P, Pimpinelli N, et al; Italian Study Group for Cutaneous Lymphomas. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas [published online ahead of print February 21, 2006]. J Clin Oncol. 2006;24(9):1376-1382.
13. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-202.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:157-181.
15. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103(10):3662-3668.
16. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90(1):354-371.
17. Grange F, Bagot M. Prognosis of primary cutaneous lymphomas [in French]. Ann Dermatol Venereol. 2002;129(1, pt 1):30-40.
18. Hembury TA, Lee B, Gascoyne RD, et al. Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases. Am J Clin Pathol. 2002;117(4):574-580.
19. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs: a distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Arch Dermatol. 1996;132(11):1304-1308.
20. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European Multicenter Study. J Clin Oncol. 2001;19(16):3602-3610.
21. Joly P, Vasseur E, Esteve E, et al; French Study Group for Cutaneous Lymphomas. Primary cutaneous medium and large cell lymphomas other than mycosis fungoides: an immunohistological and follow-up study of 54 cases. Br J Dermatol. 1995;132(4):506-512.
22. Coiffier B, Lepage E. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood. 1989;74(2):558-564.
23. Geelen FA, Vermeer MH, Meijer CJ, et al. Bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol. 1998;16(6):2080-2085.
24. Paulli M, Viglio A, Vivenza D, et al. Primary cutaneous large B-cell lymphomas of the leg: histogenetic analysis of a controversial clinicopathologic entity. Hum Pathol. 2002;33(9):937-943.
25. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671-3678.
26. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
27. Mounier N, Brière J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood. 2003;101(11):4279- 4284.